Hoku’s Commercialization Strategy Seen On Target

0
1452
Spread the love

hoku_logo.gifHoku Scientific, Inc. (HOKU) maintained an “outperform” rating and $12 target price from a Piper Jaffray analyst.

“Hoku will continue to record substantial revenue growth driven by accelerated technology development in preparation for commercial markets,” Piper analyst Jesse W. Pichel wrote in a recent report. [ more ]

I’m still waiting for Marketocracy to add this ticker to the stock universe so I can buy it for the mutual fund. If I had additional money in my personal portfolio, I would purchase more at this level.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.